Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Eisai Inc.

Xiang-Yi Li

Yimin Jiang

Bruce Decosta

Mark Spyvee

Kenzo Muramoto

Hong Du

Fabian Gusovsky

John (Yuan) Wang

Sergei I Agoulnik

Toshihiko Kaneko

Jean-Christophe P Harmange

Seiichi Kobayashi

Kouichi Kikuchi

Motohiro Soejima

Ieharu Hishinuma

Wanjun Zheng

André Lescarbeau

Huiming Zhang

Hiromitsu Yokohama

Kenichi Nomoto

Kenichi Chiba

Masanori Fujita

Lynn D Hawkins

Isao Tanaka

Boris M Seletsky

Heather Davis

Norihito Ohi

Marc Pesant

Ye Yao

Yan (Janet) Zhao

Jane Daun

Lynda Tremblay

Satoshi Yamamoto

Tomohiro Matsushima

Roch Boivin

Naoki Yoneda

Makoto Kotake

Yoshiyuki Kawakami

Hiroshi Shirota

Yoshiharu Mizui

Masaki Goto

Yoshikazu Kuboi

Yoshihito Eguchi

Hideki Sakurai

Jesse Chow

Akifumi Kimura

Takatoshi Kawai

Jiayi Wu

Charles-André Lemelin

Yong-Chun Shen

Megumi Kawada

Shawn Schiller

Frank Fang

Charles W Johannes

Mary Vermeulen

Pamela McGuiness

Erin A Murphy

Kozo Akasaka

John Wang

Atsushi Inoue

John (yuan) Wang

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R-Rare as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Multikinase inhibitors for use in the treatment of cancer

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): 

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides compounds having formula (1): wherein R-R, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Eponemycin and epoxomicin analogs and uses thereof

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Growing community of inventors

Andover, MA, United States of America

Xiang-Yi Li